Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

NCT06809595

ClinicalTrials.gov

Trial ID
T-ctgov-NCT06809595
Registry
ClinicalTrials.gov
NCT number
NCT06809595
Asset
DT120 (registry title MM120)
Sponsor, as registered
Definium Therapeutics US, Inc.
Phase
PHASE3
Indication
Generalized Anxiety Disorder
Status
ACTIVE_NOT_RECRUITING
Start date
2025-01-29
Primary completion
2026-08-13
Registered countries
Czechia, France, Germany, Poland, United Kingdom, United States
Sites
36

The sponsor's registered location list, which states intent rather than approval.

clinicaltrials.govctgov registryverified 2026-09-08

Notes on the record

Supersedes the row of the same trial_id verified 2026-08-31, per DATA LAYER rule 4. Record last updated 2026-09-04 (submitted 2026-09-03): primary_completion_date moved from 2026-08 ESTIMATED to 2026-08-13 ACTUAL; study completion 2027-05 ESTIMATED; hasResults false; enrollment 245 ACTUAL; overall status, six countries and 36 location entries unchanged. No CTIS identifier in secondaryIdInfos; the CTIS twin is 2024-513572-17-00. Bears on the open Issue 4 call: primary completion has occurred, topline not public. Fields read from the ClinicalTrials.gov v2 API record. countries is the distinct country list across all registered locations; site_count is the number of location entries, which counts a country once per site, not once per country.

Company

Through DT120 (registry title MM120): Definium Therapeutics

Cited in

Issues quoting NCT06809595 in their own text.